Literature DB >> 16170167

Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls.

Karen L Syrjala1, Shelby L Langer, Janet R Abrams, Barry E Storer, Paul J Martin.   

Abstract

PURPOSE: To determine late effects of hematopoietic cell transplantation (HCT) on health problems and health-related quality of life for 10-year survivors. PATIENTS AND METHODS: Four hundred five adults consented to the study before HCT. Medical records and standardized self-report measures were maintained prospectively. After 10 years, 137 survivors and nontransplant controls, case-matched on age, sex, and race, completed self-report of medical problems, symptoms, and health-related quality of life.
RESULTS: Survivors and controls had similar rates of hospitalization and most diseases, but survivors reported an average of 3.5 medical problems versus 1.7 for controls (P < .001). Survivors reported more musculoskeletal stiffness, cramps, weakness and joint swelling (P < .001), cataract surgery (P < .001), hepatitis C (P = .004), sexual problems for men (P = .01) and women (P < .001), restrictions in social function (P = .002), memory and attention concerns (P = .003), urinary frequency or leaking (P = .006), use of psychotropic medication (P = .009), and denial of life and health insurance (P < .001). Survivors and controls did not differ in self-reported rates of osteoporosis, hypothyroidism, employment, marital satisfaction, divorce, or psychological health.
CONCLUSION: Although indistinguishable in many respects, survivors had more medical needs than controls. Health problems were not focused on specific diseases or limited to survivors with readily identifiable risk factors. Musculoskeletal problems require both screening and research into etiologies and effective treatments. Osteoporosis and hypothyroidism may be underdiagnosed. Survivors require screening for sexual problems, urinary frequency, mood and need for antidepressants or benzodiazepines.

Entities:  

Mesh:

Year:  2005        PMID: 16170167     DOI: 10.1200/JCO.2005.12.674

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  96 in total

1.  Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation.

Authors:  Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Allison C Stover; Janet R Abrams
Journal:  J Cancer Surviv       Date:  2010-05-08       Impact factor: 4.442

2.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

3.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

Review 4.  Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature.

Authors:  Catherine E Mosher; William H Redd; Christine M Rini; Jack E Burkhalter; Katherine N DuHamel
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

Review 5.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.

Authors:  Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

6.  Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years.

Authors:  Karen L Syrjala; Brenda F Kurland; Janet R Abrams; Jean E Sanders; Julia R Heiman
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

7.  Distress, problems and supportive care needs of patients treated with auto- or allo-SCT.

Authors:  A M J Braamse; B van Meijel; O Visser; P C Huijgens; A T F Beekman; J Dekker
Journal:  Bone Marrow Transplant       Date:  2013-10-07       Impact factor: 5.483

Review 8.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

9.  Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study.

Authors:  Jessica P Hwang; Aimee K Roundtree; Sergio A Giralt; Maria Suarez-Almazor
Journal:  BMJ Support Palliat Care       Date:  2012-08-03       Impact factor: 3.568

10.  Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies.

Authors:  Bipin N Savani; Eleftheria K Koklanaris; Quan Le; Aarthi Shenoy; Stacey Goodman; A J Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.